Brief: FDA Approves Nivolumab With Chemotherapy For Previously Untreated Hodgkin Lymphoma
20/03/2026 19:08
March 20 (Reuters) - FDA: FDA APPROVES NIVOLUMAB WITH CHEMOTHERAPY FOR PREVIOUSLY UNTREATED HODGKIN LYMPHOMA FDA: GRANTED TRADITIONAL APPROVAL TO NIVOLUMAB FOR ADULTS WITH RELAPSED OR REFRACTORY CHL AFTER AUTOLOGOUS HSCT & BRENTUXIMAB VEDOTIN FDA:GRANTED TRADITIONAL APPROVAL TO NIVOLUMAB FOR ADULTS WITH RELAPSED/REFRACTORY CHL AFTER 3/MORE LINES OF SYSTEMIC THERAPY INCLUDING AUTOLOGOUS HSCT Further company coverage: BMY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC